All Patients With Advanced Fibrosis Should Continue to Be Screened for Hepatocellular Carcinoma After Sustained Virological Response of Hepatitis C Virus
Ruben Khan, Sugir Velpari, Sean Koppe – 14 December 2018
p53 Up‐regulated Modulator of Apoptosis Induction Mediates Acetaminophen‐Induced Necrosis and Liver Injury in Mice
Dongshi Chen, Hong‐Min Ni, Lei Wang, Xiaowen Ma, Jian Yu, Wen‐Xing Ding, Lin Zhang – 14 December 2018 – Acetaminophen (APAP) overdose is one of the leading causes of hepatotoxicity and acute liver failure in the United States. Accumulating evidence suggests that hepatocyte necrosis plays a critical role in APAP‐induced liver injury (AILI). However, the mechanisms of APAP‐induced necrosis and liver injury are not fully understood.
Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection
Jordan J. Feld, Norah A. Terrault, Hsing‐Hua S. Lin, Steven H. Belle, Raymond T. Chung, Naoky Tsai, Mandana Khalili, Robert Perrillo, Stewart L. Cooper, Marc G. Ghany, Harry L.A. Janssen, Anna S. Lok, for the Hepatitis B Research Network – 14 December 2018 – Monotherapy with interferon or nucleoside analog is generally not recommended during the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase.
MicroRNAs: Unfolding the Link Between Inositol‐Requiring Enzyme 1α and Fatty Liver
Xiaoying Liu, Richard M. Green – 14 December 2018
Hepatitis C Virus Standard of Care: A Rapid Evolution and Considerations for Acute Hepatitis C Virus
Tram T. Tran – 14 December 2018
Epidemiology of Hepatitis C
Syed‐Mohammed Jafri, Stuart C. Gordon – 14 December 2018
PRO: Patients With Hepatitis C Virus With Pretreatment Metavir Stage 3 Fibrosis Do Not Require Hepatocellular Carcinoma Surveillance After Sustained Virological Response
Amoah Yeboah‐Korang, Nicole M. Gentile, Claus J. Fimmel – 14 December 2018
Rationing Care: Barriers to Direct‐Acting Antiviral Treatment in Medicaid Treatment Criteria
Phil Waters, Tina Broder – 14 December 2018
Hepatitis C Virus in the Modern Direct‐Acting Antiviral Era: Where Have All the Special Populations Gone?
Christian B. Ramers, Stacey B. Trooskin – 14 December 2018
Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection
Jordan J. Feld, Norah A. Terrault, Hsing‐Hua S. Lin, Steven H. Belle, Raymond T. Chung, Naoky Tsai, Mandana Khalili, Robert Perrillo, Stewart L. Cooper, Marc G. Ghany, Harry L.A. Janssen, Anna S. Lok, for the Hepatitis B Research Network – 14 December 2018 – Monotherapy with interferon or nucleoside analog is generally not recommended during the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase.